Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations

Yuka Ohata, Yoshiko Tomita, Mitsunobu Nakayama, Tsuneo Kozuki, Keisuke Sunakawa, Yusuke Tanigawara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration (%T>MIC) and for optimal dosing of meropenem in pediatric patients. After dosing at 20mg/kg t.i.d. by 0.5-h infusion (approved standard dose for pediatric patients in Japan), the target value of 50%T>MIC was achieved, indicating that 20mg/kg t.i.d. by 0.5-h infusion is effective for susceptible bacteria. In contrast, for bacteria with higher MICs such as Pseudomonas aeruginosa (MIC ≥ 2 μg/mL), the probability of target attainment of 50%T>MIC was 60.7% at a dose of 40mg/kg t.i.d. by 0.5-h infusion (highest dose approved for pediatric patients in Japan). The simulations described in this article indicated that 40 mg/kg t.i.d. with a longer infusion duration (e.g., 4 h) is more effective against bacteria with a MIC higher than 2 μg/mL. The predicted probability of target attainment for 50%T>MIC (97.0%) was well correlated not only to the microbiological efficacy rate (97.0%) but also to the clinical efficacy rate (95.9%) in the present phase 3 study.

Original languageEnglish
Pages (from-to)523-531
Number of pages9
JournalDrug Metabolism and Pharmacokinetics
Volume26
Issue number5
DOIs
Publication statusPublished - 2011

Fingerprint

meropenem
Pharmacokinetics
Pediatrics
Bacteria
Japan
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Population
Communicable Diseases

Keywords

  • %T>MIC
  • Meropenem
  • Monte Carlo simulation
  • Pediatrics
  • PK/PD

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmaceutical Science

Cite this

Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. / Ohata, Yuka; Tomita, Yoshiko; Nakayama, Mitsunobu; Kozuki, Tsuneo; Sunakawa, Keisuke; Tanigawara, Yusuke.

In: Drug Metabolism and Pharmacokinetics, Vol. 26, No. 5, 2011, p. 523-531.

Research output: Contribution to journalArticle

Ohata, Yuka ; Tomita, Yoshiko ; Nakayama, Mitsunobu ; Kozuki, Tsuneo ; Sunakawa, Keisuke ; Tanigawara, Yusuke. / Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. In: Drug Metabolism and Pharmacokinetics. 2011 ; Vol. 26, No. 5. pp. 523-531.
@article{da6e61c9506548a6aa280510bee19479,
title = "Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations",
abstract = "A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration ({\%}T>MIC) and for optimal dosing of meropenem in pediatric patients. After dosing at 20mg/kg t.i.d. by 0.5-h infusion (approved standard dose for pediatric patients in Japan), the target value of 50{\%}T>MIC was achieved, indicating that 20mg/kg t.i.d. by 0.5-h infusion is effective for susceptible bacteria. In contrast, for bacteria with higher MICs such as Pseudomonas aeruginosa (MIC ≥ 2 μg/mL), the probability of target attainment of 50{\%}T>MIC was 60.7{\%} at a dose of 40mg/kg t.i.d. by 0.5-h infusion (highest dose approved for pediatric patients in Japan). The simulations described in this article indicated that 40 mg/kg t.i.d. with a longer infusion duration (e.g., 4 h) is more effective against bacteria with a MIC higher than 2 μg/mL. The predicted probability of target attainment for 50{\%}T>MIC (97.0{\%}) was well correlated not only to the microbiological efficacy rate (97.0{\%}) but also to the clinical efficacy rate (95.9{\%}) in the present phase 3 study.",
keywords = "{\%}T>MIC, Meropenem, Monte Carlo simulation, Pediatrics, PK/PD",
author = "Yuka Ohata and Yoshiko Tomita and Mitsunobu Nakayama and Tsuneo Kozuki and Keisuke Sunakawa and Yusuke Tanigawara",
year = "2011",
doi = "10.2133/dmpk.DMPK-11-RG-027",
language = "English",
volume = "26",
pages = "523--531",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "5",

}

TY - JOUR

T1 - Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations

AU - Ohata, Yuka

AU - Tomita, Yoshiko

AU - Nakayama, Mitsunobu

AU - Kozuki, Tsuneo

AU - Sunakawa, Keisuke

AU - Tanigawara, Yusuke

PY - 2011

Y1 - 2011

N2 - A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration (%T>MIC) and for optimal dosing of meropenem in pediatric patients. After dosing at 20mg/kg t.i.d. by 0.5-h infusion (approved standard dose for pediatric patients in Japan), the target value of 50%T>MIC was achieved, indicating that 20mg/kg t.i.d. by 0.5-h infusion is effective for susceptible bacteria. In contrast, for bacteria with higher MICs such as Pseudomonas aeruginosa (MIC ≥ 2 μg/mL), the probability of target attainment of 50%T>MIC was 60.7% at a dose of 40mg/kg t.i.d. by 0.5-h infusion (highest dose approved for pediatric patients in Japan). The simulations described in this article indicated that 40 mg/kg t.i.d. with a longer infusion duration (e.g., 4 h) is more effective against bacteria with a MIC higher than 2 μg/mL. The predicted probability of target attainment for 50%T>MIC (97.0%) was well correlated not only to the microbiological efficacy rate (97.0%) but also to the clinical efficacy rate (95.9%) in the present phase 3 study.

AB - A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration (%T>MIC) and for optimal dosing of meropenem in pediatric patients. After dosing at 20mg/kg t.i.d. by 0.5-h infusion (approved standard dose for pediatric patients in Japan), the target value of 50%T>MIC was achieved, indicating that 20mg/kg t.i.d. by 0.5-h infusion is effective for susceptible bacteria. In contrast, for bacteria with higher MICs such as Pseudomonas aeruginosa (MIC ≥ 2 μg/mL), the probability of target attainment of 50%T>MIC was 60.7% at a dose of 40mg/kg t.i.d. by 0.5-h infusion (highest dose approved for pediatric patients in Japan). The simulations described in this article indicated that 40 mg/kg t.i.d. with a longer infusion duration (e.g., 4 h) is more effective against bacteria with a MIC higher than 2 μg/mL. The predicted probability of target attainment for 50%T>MIC (97.0%) was well correlated not only to the microbiological efficacy rate (97.0%) but also to the clinical efficacy rate (95.9%) in the present phase 3 study.

KW - %T>MIC

KW - Meropenem

KW - Monte Carlo simulation

KW - Pediatrics

KW - PK/PD

UR - http://www.scopus.com/inward/record.url?scp=80055088020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055088020&partnerID=8YFLogxK

U2 - 10.2133/dmpk.DMPK-11-RG-027

DO - 10.2133/dmpk.DMPK-11-RG-027

M3 - Article

VL - 26

SP - 523

EP - 531

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 5

ER -